Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

NDT Pharmaceuticals Inc (PK:NDTP)

Business Focus: Pharmaceuticals

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEC Form 4 filings for NDTP*US within the last 6 months
Loading...
See all filings within the past 6 months

Valuation Ratios

Industry
Sector
Beta
N/A
--
--
Price to Sales - TTM
--
2.45
3.32
Price to Book - most recent quarter
0.36
1.91
2.21
Price to Cash Flow per share - TTM
--
12.81
14.62
Price to Free Cash Flow per share - TTM
--
19.04
24.76
See all valuations

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

NDT Pharmaceuticals, Inc. is a Canada-based company, which is focused on developing nutraceutical and pharmaceutical products utilizing intellectual property. The Company has acquired all rights under a Sponsored Research Agreement with the University of Pennsylvania, including rights to use the University's Nanoscale Particle Complex (NPC) technology. The intellectual property includes a versatile and widely applicable biotechnology asset base, including the Nanoscale Particle Complex (NPC) technology, which represents phospholipid-based nano-encapsulation delivery systems that create instant delivery of payloads into the bloodstream, beginning through the membranes of the mouth. The NPC technology also incorporates a potent active ingredient that stimulates repair of damaged cell tissue branded by the Company as Cell Armor.

See business summary

 

Twitter

Search (past week) for $NDTP

  • No tweets found